What is AST?
AST operates at the critical intersection of biotechnology and industrial engineering, specializing in the design and deployment of advanced aseptic filling and closing systems. The company provides essential infrastructure for the pharmaceutical industry, offering flexible, integrated fill-finish solutions that adhere to the most stringent global regulatory standards. Their portfolio, which spans from automated container filling to complex aseptic processing, serves a diverse clientele ranging from large-scale biologics manufacturers to specialized cell and gene therapy developers. By prioritizing precision and compliance, AST has established itself as a foundational partner in the drug development lifecycle, ensuring the integrity and safety of sensitive medical products.
How much funding has AST raised?
AST has raised a total of $350K across 1 funding round:
Debt
$350K
Debt (2020): $350K with participation from PPP
Key Investors in AST
PPP
Public-Private Partnership
What's next for AST?
With the infusion of this late-stage capital, AST is expected to scale its manufacturing capabilities to meet the surging global demand for biologics and personalized medicine. The strategic roadmap likely involves expanding its footprint in automated aseptic processing, further integrating digital monitoring systems to enhance production efficiency, and potentially exploring new geographic markets. As the pharmaceutical industry continues to shift toward more complex, small-batch manufacturing, AST's focus on modular and adaptable technology will be a key driver in maintaining its competitive edge. The company is well-positioned to capitalize on the ongoing evolution of drug delivery systems, ensuring that its technological infrastructure remains at the forefront of the life sciences supply chain.
See full AST company page
